Cytolytic activity score as a biomarker for antitumor immunity and clinical outcome in patients with gastric cancer

Hu, Qingjiang; Nonaka, Kentaro; Wakiyama, Hiroaki; Miyashita, Yu; Fujimoto, Yoshiaki; Jogo, Tomoko; Hokonohara, Kentaro; Nakanishi, Ryota; Hisamatsu, Yosuke; Ando, Koji; Kimura, Yasue; Masuda, Takaaki; Oki, Eiji; Mimori, Koshi; Oda, Yoshinao; Mori, Masaki

doi:10.1002/cam4.3828

Cited by 26 publications

(29 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The immune activity of most of the immune functions was higher in the low-risk subgroup, such as checkpoint, cytolytic activity, and type II IFN response. The immune cytolytic activity score reflects antitumor immunity and predicts clinical outcomes of patients with GC ( Hu et al, 2021 ). Type II IFN (IFN-γ) is a critical driver of programmed death ligand-1 (PD-L1) expression in cancer and host cells ( Ayers et al, 2017 ).…”

Section: Discussionmentioning

confidence: 99%

Prognostic Ferroptosis-Related lncRNA Signatures Associated With Immunotherapy and Chemotherapy Responses in Patients With Stomach Cancer

et al. 2022

View full text Add to dashboard Cite

Ferroptosis is associated with the prognosis and therapeutic responses of patients with various cancers. LncRNAs are reported to exhibit antitumor or oncogenic functions. Currently, few studies have assessed the combined effects of ferroptosis and lncRNAs on the prognosis and therapy of stomach cancer. In this study, transcriptomic and clinical data were downloaded from TCGA database, and ferroptosis-related genes were obtained from the FerrDb database. Through correlation analysis, Cox analysis, and the Lasso algorithm, 10 prognostic ferroptosis-related lncRNAs (AC009299.2, AC012020.1, AC092723.2, AC093642.1, AC243829.4, AL121748.1, FLNB-AS1, LINC01614, LINC02485, LINC02728) were screened to construct a prognostic model, which was verified in two test cohorts. Risk scores for patients with stomach cancer were calculated, and patients were divided into two risk groups. The low-risk group, based on the median value, had a longer overall survival time in the KM curve, and a lower proportion of dead patients in the survival distribution curve. Potential mechanisms and possible functions were revealed using GSEA and the ceRNA network. By integrating clinical information, the association between lncRNAs and clinical features was analyzed and several features affecting prognosis were identified. Then, a nomogram was developed to predict survival rates, and its good predictive performance was indicated by a relatively high C-index (0.67118161) and a good match in calibration curves. Next, the association between these lncRNAs and therapy was explored. Patients in the low-risk group had an immune-activating environment, higher immune scores, higher TMB, lower TIDE scores, and higher expression of immune checkpoints, suggesting they might receive a greater benefit from immune checkpoint inhibitor therapy. In addition, a significant difference in the sensitivity to mitomycin. C, cisplatin, and docetaxel, but not etoposide and paclitaxel, was observed. In summary, this model had guiding significance for prognosis and personalized therapy. It helped screen patients with stomach cancer who might benefit from immunotherapy and guided the selection of personalized chemotherapeutic drugs.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic Ferroptosis-Related lncRNA Signatures Associated With Immunotherapy and Chemotherapy Responses in Patients With Stomach Cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In recent years, the CYT score has been used to predict the prognosis of some tumours. Low CYT scores represent weak antitumour immunity in GC, resulting in a poor prognosis [ 27 ] and are also associated with poor outcomes in HCC [ 28 ].…”

Section: Resultsmentioning

confidence: 99%

Comprehensive Multiomic Analysis Identified TUBA1C as a Potential Prognostic Biological Marker of Immune-Related Therapy in Pan-Cancer

Zou

Wang

Fan

2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

TUBA1C is correlated with an unfavourable prognosis and the infiltration of immune cells in several cancers. However, its function as a significant biomarker for the prognosis of immunotherapy in pan-cancer remains unclear. This study aims at assessing the role of TUBA1C in pan-cancer at multiple levels, including mutations, gene expression, methylation, m6A methylation, and immune cell infiltration levels. Data retrieved from major public databases, such as TCGA, GEO, GTEx, GSCA, CancerSEA, HPA, and RNAactDrugs, revealed that TUBA1C expression was high in 33 cancer types. Survival analysis revealed that TUBA1C was a poor prognostic factor for 12 tumour types, and mutations, CNVs, and methylation affected the prognosis of some cancer types. Furthermore, TUBA1C was found to be related to immune-related genes, immune cell infiltration, and the immune microenvironment. In addition, the sensitivity of 10 anticancer drugs was associated with high TUBA1C expression. Therefore, TUBA1C may serve as a viable prognostic biomarker for immunotherapy of pan-cancer.

show abstract

“…Numerous elements of cancer biology have been identified to involve chemokines and their receptors; their possible targets have been evaluated in several studies, and chemokine receptor inhibitors have been used in clinical practice in hematologic malignancies [ 38 ]. In patients with gastric cancer, the cytolytic activity score can be employed as a biomarker in antitumor immunity and clinical prognosis [ 39 ] but also to evaluate anticancer immunity in colorectal cancer [ 40 ]. Nuclear factor-κB (NF-κB), which promotes inflammation, is a central mediator of the inflammatory process, and activation of NF-κB is also prevalent in cancer, which is mainly driven by inflammatory cytokines in the tumor microenvironment [ 41 ]; thus, inflammation promotion plays a crucial role in tumorigenesis.…”

Section: Discussionmentioning

confidence: 99%

Expression patterns and prognostic value of key regulators associated with m7G RNA modification based on all gene expression in colon adenocarcinoma

et al. 2023

View full text Add to dashboard Cite

Background N7-methylguanosine (m7G) is present in a wide variety of organisms and has important roles. m7G has been reported to be involved in multiple biological processes, and recent studies have reported that changes in RNA modifications result in tumor cellular transformation and cancer, such as colon adenocarcinoma, lung cancer, and intrahepatic cholangiocarcinoma. However, little is known about the function of the m7G in colon adenocarcinoma. Methods We established two clusters based on the expression of all genes associated with m7G to explore the expression pattern of 31 key regulatory factors of m7G RNA and assess the prognostic value of regulatory factors. Wilcoxon test and differential box line plots were applied for bioinformatics analysis. Receiver Operating and Kaplan‒Meier curves were utilized to evaluate the prognostic value. Finally, four genes' expression in the colon cancer cell line was confirmed by qRT-PCR. Results From The Cancer Genome Atlas database, we found that the expression levels of 25 out of the 31 key N7-methylguanosine RNA modification regulators were significantly different in colon adenocarcinoma. According to 25 methylation regulators’ expression, we identified two subgroups by consensus clustering, in which the prognosis was worse in Group 2 than in Group 1 and was significantly correlated with age. Cluster 2 was significantly enriched in tumor-associated pathways, and immune cells were highly infiltrated in Cluster 1 but weakly infiltrated in Cluster 2. Further results indicated that this risk profile may serve as a standalone predictive factor for colon adenocarcinoma, and the four genetic risk profiles’ prognostic relatedness was successfully verified through Gene Expression Omnibus dataset. At last, A nomogram for prognosis was created according to age, sex, histological grading, clinicopathological staging, and hazard score to accurately predict patient prognosis in colon adenocarcinoma. We successfully validated the differential expression of four genes using qRT-PCR. Conclusions In the present study, we revealed the important contribution of key regulators associated with m7G RNA modifications based on all gene expression in colon adenocarcinoma and developed a signature of risk that serves as a promising prognostic marker for patients with colon adenocarcinoma.

show abstract

Cytolytic activity score as a biomarker for antitumor immunity and clinical outcome in patients with gastric cancer

Abstract: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Cited by 26 publications

References 38 publications

Prognostic Ferroptosis-Related lncRNA Signatures Associated With Immunotherapy and Chemotherapy Responses in Patients With Stomach Cancer

Prognostic Ferroptosis-Related lncRNA Signatures Associated With Immunotherapy and Chemotherapy Responses in Patients With Stomach Cancer

Comprehensive Multiomic Analysis Identified TUBA1C as a Potential Prognostic Biological Marker of Immune-Related Therapy in Pan-Cancer

Expression patterns and prognostic value of key regulators associated with m7G RNA modification based on all gene expression in colon adenocarcinoma

Contact Info

Product

Resources

About